The Role of Chemotherapy in Prostate Cancer
William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.
William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the role of chemotherapy in castration-resistant prostate cancer (CRPC).
Clinical Pearls
- Chemotherapy has been used to treat CRPC for a long time
- Docetaxel has become a key chemotherapy agent used to treat CRPC for the last decade
- Physicians have tried to use docetaxel with other newer targeted agents, but combining agents with docetaxel has not shown any clinical benefit
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
